A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

NCT05024032 on ClinicalTrials.gov · last registry update 2024-01-19

A small phase 3 — 210 participants, against a typical 424. The sponsor logged completion for 27 December 2022. Primary outcome, as filed: Mean Percent Change From Baseline in Body Weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 210
Started: 2021-09-01
Primary completion: 2022-12-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Percent Change From Baseline in Body Weight

Conditions studied

Obesity · Overweight · Metabolism and Nutrition Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.